Patent DE932077C successfully refreshed from Google Patents.
US5318957A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method of stimulating angiogenesis
Assignee: United States Department of Health and Human Services
•
Filing: 1992-09-02
•
Granted: 1994-06-07
•
Expires: 2012-09-02
Abstract
Abstract A method of stimulating angiogenesis in a mammal by administering to a mammal a haptoglobin in an amount effective to stimulate angiogenesis, and a pharmaceutical composition containing a haptoglobin and a pharmaceutically acceptable carrier.
Inventors
- 👤 Maria C. Cid
- 👤 Derrick S. Grant
- 👤 Hynda K. Kleinman
- 👤 Gary S. Hoffman
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 16:28
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/46; C07K14/47; C07K14/4701; C07K14/4717; A; A61; A61K; A61K38/00
Claims Analysis
Total Claims: 20
Claim 1
Independent Claim
24 words
A method of stimulating angiogenesis in a mammal, which method comprises administering to a mammal a haptoglobin in an amount effective to stimulate angiogenesis.
Claim 2
Independent Claim
24 words
A method of stimulating angiogenesis in a mammal, which method comprises administering to a mammal a haptoglobin in an amount effective to stimulate angiogenesis.
Claim 3
Dependent Claim
35 words
The method of claim 1, wherein said haptoglobin is selected from the group consisting of haptoglobin 1.1, haptoglobin 2.1, haptoglobin 2.2, the haptoglobins found in the sera of patients with systemic vasculitis, and mixtures thereof.
Claim 4
Dependent Claim
11 words
The method of claim 2, wherein said haptoglobin is haptoglobin 2.2.
Claim 5
Dependent Claim
11 words
The method of claim 2, wherein said haptoglobin is haptoglobin 2.1.
Claim 6
Dependent Claim
11 words
The method of claim 2, wherein said haptoglobin is haptoglobin 1.1.
Claim 7
Dependent Claim
29 words
The method of claim 2, wherein said haptoglobin is one or a mixture of two or more of the haptoglobins found in the sera of patients with systemic vasculitis.
Claim 8
Dependent Claim
11 words
The method of claim 2, wherein said mammal is a human.
Claim 9
Dependent Claim
28 words
The method of claim 7, wherein said haptoglobin is administered in an amount sufficient to result in a haptoglobin concentration of at least about 2 mg/ml blood plasma.
Claim 10
Independent Claim
28 words
A method of stimulating angiogenesis in mammalian tissue in vitro, which method comprises contacting mammalian tissue in vitro with a haptoglobin in an amount effective to stimulate angiogenesis.
Claim 11
Independent Claim
28 words
A method of stimulating angiogenesis in mammalian tissue in vitro, which method comprises contacting mammalian tissue in vitro with a haptoglobin in an amount effective to stimulate angiogenesis.
Claim 12
Dependent Claim
35 words
The method of claim 9, wherein said haptoglobin is selected from the group consisting of haptoglobin 1.1, haptoglobin 2.1, haptoglobin 2.2, the haptoglobins found in the sera of patients with systemic vasculitis, and mixtures thereof.
Claim 13
Dependent Claim
11 words
The method of claim 10, wherein said haptoglobin is haptoglobin 2.2.
Claim 14
Dependent Claim
11 words
The method of claim 10, wherein said haptoglobin is haptoglobin 2.1.
Claim 15
Dependent Claim
11 words
The method of claim 10, wherein said haptoglobin is haptoglobin 1.1.
Claim 16
Dependent Claim
29 words
The method of claim 10, wherein said haptoglobin is one or a mixture of two or more of the haptoglobins found in the sera of patients with systemic vasculitis.
Claim 17
Dependent Claim
12 words
The method of claim 10, wherein said mammalian tissue is human tissue.
Claim 18
Dependent Claim
19 words
A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a haptoglobin in a therapeutically effective amount to stimulate angiogenesis.
Claim 19
Dependent Claim
19 words
A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a haptoglobin in a therapeutically effective amount to stimulate angiogenesis.
Claim 20
Dependent Claim
36 words
The pharmaceutical composition of claim 16, wherein said haptoglobin is selected from the group consisting of haptoglobin 1.1, haptoglobin 2.1, haptoglobin 2.2, the haptoglobins found in the sera of patients with systemic vasculitis, and mixtures thereof.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1997-06-06 | 1997-12-06 | 1998-06-07 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2001-06-06 | 2001-12-06 | 2002-06-07 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2005-06-06 | 2005-12-06 | 2006-06-07 | $7700.00 | Window Closed / Lapsed |